Literature DB >> 6608982

Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography.

E S Garnett, C Nahmias, G Firnau.   

Abstract

[18F]6-fluoro-L-dopa and positron emission tomography has been used to study intracerebral dopamine distribution in five control subjects and six patients with hemiparkinsonism. In the control subjects striatal, frontal and cingulate accumulations were clearly seen. In addition 18F concentrated in the region of the insula and the parietal lobe. In the patients striatal accumulation 18F was reduced in the contralateral striatum, especially in the putamen. The uniformity of distribution of 18F in the striatum on the side of the parkinsonian signs was also irregular. This finding is consonant with the suggestion that intracerebral compensatory mechanisms prevent the manifestation of intracerebral dopamine deficiency from becoming obvious until a late stage of the disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608982     DOI: 10.1017/s0317167100046369

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  19 in total

1.  Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Authors:  J O Rinne; H Ruottinen; J Bergman; M Haaparanta; P Sonninen; O Solin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

2.  The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson's disease.

Authors:  M Jahanshahi; R G Brown; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

Review 3.  PET and movement disorders.

Authors:  D J Brooks; R S Frackowiak
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 4.  Approaches to the design of biochemical probes for positron emission tomography.

Authors:  J R Barrio
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

5.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

Review 6.  Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management.

Authors:  Toshihito Suzuki; Hisashi Matsuzaka
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 7.  Early detection of Parkinson's disease. Implications for treatment.

Authors:  R Di Paola; R J Uitti
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

8.  Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.

Authors:  Catherine L Gallagher; Terrence R Oakes; Sterling C Johnson; Moo K Chung; James E Holden; Barbara B Bendlin; Donald G McLaren; Guofan Xu; Robert J Nickles; Robert Pyzalski; Onofre DeJesus; W Douglas Brown
Journal:  Mov Disord       Date:  2011-03-29       Impact factor: 10.338

9.  6-18F-L-dopa imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys.

Authors:  D J Doudet; H Miyake; R T Finn; C A McLellan; T G Aigner; R Q Wan; H R Adams; R M Cohen
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

10.  Cognition and cerebral blood flow in lateralised parkinsonism: lack of functional lateral asymmetries.

Authors:  A Agniel; P Celsis; G Viallard; J L Montastruc; O Rascol; J F Demonet; J P Marc-Vergnes; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.